News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 06:00:00 21/08/26 am AEST			5-day change	1st Jan Change
14.78 ^USD	-6.28%		-6.69%	-5.74%

07/08	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT

All News

Mentions Relevance

07/08	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M	MT
06/08	Monte Rosa Therapeutics: Q2 Earnings Snapshot	AQ
06/08	Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates	GL
01/08	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT
03/07	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
30/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
30/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI
30/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000 Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000 Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Small Cap Comp Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2500 Value Benchmark	CI
03/06	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
08/05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT
07/05	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
07/05	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ